Jonathan Wise

Jonathan Wise

Of Counsel

Jonathan Wise is a member of Greenberg Traurig’s Intellectual Property Litigation team. Prior to joining the firm, Jon was with Teva Pharmaceuticals from 2010 until 2018. As Associate General Counsel of IP Litigation at Teva Pharmaceuticals, he coordinated and executed patent litigation strategy with outside counsel on dozens of U.S. pharmaceutical patent cases filed under the Hatch-Waxman Act; managed a team of lawyers overseeing Teva’s U.S. generic patent cases; regularly advised senior management and communications teams on litigation risks and results; conducted internal training on patent litigation and the U.S. discovery process at Teva sites around the world; and negotiated several case settlements.

Prior to serving as in-house counsel, Jon litigated patent cases at an intellectual property boutique in New York City. There, he worked on a wide variety of cases representing brand and generic pharmaceutical companies, as well as companies focused on DVDs, computerized controllers, and medical devices.

Jon has also represented veterans in pro bono cases before the U.S. Court of Appeals for Veterans Claims to help them obtain their service-connected disability benefits.

Concentrations

  • Patent litigation
  • ANDA Hatch-Waxman litigation
Mehr +

Expertise

Erfahrung

  • Keryx Biopharmaceuticals, Inc. v. Teva Pharmaceuticals USA, Inc.:  Representing Teva in its Paragraph IV challenge to Keryx’s patents in the District of Delaware relating to a generic version of Auryxia®.
  • Collegium Pharmaceutical, Inc. v. Teva Pharmaceuticals USA, Inc.:  Representing Teva in its Paragraph IV challenge to Collegium’s patents in the District of Delaware relating to a generic version of Xtampza® ER.
  • Egalet US, Inc. v. Teva Pharmaceuticals USA, Inc.:  Represented Teva in its Paragraph IV challenge to Egalet’s patents in the District of Delaware relating to a generic version of Arymo® ER. Teva obtained a dismissal of the case with prejudice.
  • Vifor Fresenius Medical Care Renal Pharma Ltd. v. Teva Pharmaceuticals USA, Inc.:  Representing Teva in its Paragraph IV challenge to Vifor’s patents in the District of Delaware relating to a generic version of Velphoro®.
  • Worked with teams to obtain favorable trial and appellate court decisions in Hatch-Waxman cases involving drug products Actonel®, Aloxi®, Ampyra®, Atelvia®, Celebrex®, Lovaza®, Namenda XR®, and OxyContin®
  • Negotiated settlements in Hatch-Waxman cases involving drug products Aubagio®, Bunavail®, Celebrex®, Cubicin®, Fazaclo®, Folotyn®, Lunesta®, Namenda XR®, Nexium 24hr OTC, Oxycontin®, Rozerem®, Travatan Z®, Viagra®, Vytorin®, Zetia®, Zyvox®
  • Served as a member of the team representing Teva in the 2017 LMG Life Sciences Patent Impact Case of the Year (GlaxoSmithKline LLC, et al. v. Teva Pharmaceuticals USA, Inc.).°
  • Litigated patent cases for technology companies specializing in DVDs and controllers used in cooking ovens.°
  • Represented disabled veterans in pro-bono cases before the U.S. Court of Appeals for Veterans Claims. (Coderre v. Peak, No. 06-2266; Schuh v. Gibson, No. 12-3100).°

°The above representations were handled by Mr. Wise prior to his joining Greenberg Traurig, LLP.

  • Associate General Counsel – IP Litigation, Teva Pharmaceuticals, 2010-2018
  • Legal Intern, Hon. Arthur J. Gajarsa, U.S. Court of Appeals for the Federal Circuit

Ausbildung

Akademische Ausbildung
  • J.D., University of New Hampshire School of Law, 2005
    • Chief Articles Editor, Pierce Law Review
  • M.B.A., Temple University Fox School of Business
  • B.S., Chemical Engineering, Pennsylvania State University, 2002
Zulassung
  • Pennsylvania
  • New York
  • U.S. Patent and Trademark Office